- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge | ||
| Fr | Agomab, SpyGlass Pharma head to Nasdaq with IPOs totalling $350M | ||
| Do | Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA | ||
| Do | Angitia raises $130M to challenge Amgen with bone-building bispecifics | ||
| Do | Flagship-founded antibody biotech Generate is latest to mull IPO | ||
| Do | Quell halts liver transplant Treg trial to focus on preclinical 'chill not kill' candidate | ||
| Do | Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024 | ||
| Mi | Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout | ||
| Mi | Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates | ||
| Mi | Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq | ||
| Mi | GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight' | ||
| Mi | Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1 | ||
| Di | HHS launches $100M antiviral prize to develop broad-spectrum therapies | ||
| Di | Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed | ||
| Di | Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges | ||
| Di | Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b | ||
| Di | NMD flunks rare disease trial, but flexes secondary data to accelerate program | ||
| Mo | Novo's CagriSema tops semaglutide in ph. 3 diabetes study | ||
| Mo | GSK plans to lay off up to 350 R&D workers across US, UK | ||
| Mo | GSK gives back rights to Wave's genetic disease RNA editor | ||
| Mo | Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again | ||
| Mo | China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug | ||
| Mo | Skye links CB1-Wegovy combo to 22.3% weight loss after a year in extension of failed ph. 2 study | ||
| Mo | Roche's return to RNA continues with $1.7B deal for Sanegene program | ||
| Mo | Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.